Effects of imidazoline-like drugs on liver and adipose tissues, and their role in preventing obesity and associated cardio-metabolic disorders.
Fiche publication
Date publication
mars 2019
Journal
International journal of obesity (2005)
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DALI-YOUCEF Nassim, Pr PONS Françoise
Tous les auteurs :
Aubertin G, Weiss M, Traversi F, Benameur D, Choquet P, Dali-Youcef N, Pons F, Sigrist S, Greney H, Monassier L, Bousquet P, Niederhoffer N
Lien Pubmed
Résumé
We previously observed that selective agonists of the sympatho-inhibitory I imidazoline receptors (LNP ligands) have favorable effects on several cardiovascular and metabolic disorders defining the metabolic syndrome, including body weight. The objectives of this study were to explore the effects of LNPs on adiposity and the mechanisms involved, and to evaluate their impact on metabolic homeostasis.
Référence
Int J Obes (Lond). 2019 Mar 29;: